OA10564A - A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane - Google Patents

A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane Download PDF

Info

Publication number: OA10564A
Authority: OA; OAPI
Prior art keywords: vaccines; pharmaceutical preparation; antigens; preparation according; caprylic
Prior art date: 1993-02-15

Application number

OA60698A

Other languages

English (en)

Inventor

Sveinbjoern Gizurarson

Iver Heron

Original Assignee

Lyfjathroun H F

Seruminstitut Statens

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-15

Filing date

1995-08-11

Publication date

2002-06-20

1995-08-11 Application filed by Lyfjathroun H F, Seruminstitut Statens filed Critical Lyfjathroun H F

2002-06-20 Publication of OA10564A publication Critical patent/OA10564A/en

Links

229960005486 vaccine Drugs 0.000 title claims abstract 17
239000000427 antigen Substances 0.000 title claims abstract 12
102000036639 antigens Human genes 0.000 title claims abstract 12
108091007433 antigens Proteins 0.000 title claims abstract 12
241000124008 Mammalia Species 0.000 title claims abstract 6
238000011200 topical administration Methods 0.000 title claims abstract 5
239000012528 membrane Substances 0.000 title claims abstract 4
239000000825 pharmaceutical preparation Substances 0.000 title claims 14
239000000203 mixture Substances 0.000 claims abstract 8
239000002671 adjuvant Substances 0.000 claims abstract 7
229920001214 Polysorbate 60 Polymers 0.000 claims abstract 6
239000004359 castor oil Substances 0.000 claims abstract 6
235000019438 castor oil Nutrition 0.000 claims abstract 6
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract 6
238000002360 preparation method Methods 0.000 claims abstract 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 4
150000002270 gangliosides Chemical class 0.000 claims abstract 4
-1 polyoxyethylene Polymers 0.000 claims abstract 4
239000003981 vehicle Substances 0.000 claims abstract 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
241000700605 Viruses Species 0.000 claims 5
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 5
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 3
125000002252 acyl group Chemical group 0.000 claims 3
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 3
239000003795 chemical substances by application Substances 0.000 claims 3
239000000546 pharmaceutical excipient Substances 0.000 claims 3
150000003626 triacylglycerols Chemical class 0.000 claims 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
241000725303 Human immunodeficiency virus Species 0.000 claims 2
229960001212 bacterial vaccine Drugs 0.000 claims 2
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 2
229930182830 galactose Natural products 0.000 claims 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 2
229940070765 laurate Drugs 0.000 claims 2
210000004877 mucosa Anatomy 0.000 claims 2
229940060155 neuac Drugs 0.000 claims 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
229940049964 oleate Drugs 0.000 claims 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
244000045947 parasite Species 0.000 claims 2
239000000126 substance Substances 0.000 claims 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
APRRQJCCBSJQOQ-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid Chemical group OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 APRRQJCCBSJQOQ-UHFFFAOYSA-N 0.000 claims 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
241000606161 Chlamydia Species 0.000 claims 1
206010008631 Cholera Diseases 0.000 claims 1
241000709661 Enterovirus Species 0.000 claims 1
241000991587 Enterovirus C Species 0.000 claims 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
241000606768 Haemophilus influenzae Species 0.000 claims 1
206010024229 Leprosy Diseases 0.000 claims 1
241000712079 Measles morbillivirus Species 0.000 claims 1
241000711386 Mumps virus Species 0.000 claims 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims 1
208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
201000005702 Pertussis Diseases 0.000 claims 1
241000711798 Rabies lyssavirus Species 0.000 claims 1
241000725643 Respiratory syncytial virus Species 0.000 claims 1
241000702670 Rotavirus Species 0.000 claims 1
241000710799 Rubella virus Species 0.000 claims 1
241000607768 Shigella Species 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
206010043376 Tetanus Diseases 0.000 claims 1
229940124532 absorption promoter Drugs 0.000 claims 1
150000001298 alcohols Chemical class 0.000 claims 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
229940106189 ceramide Drugs 0.000 claims 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
125000001549 ceramide group Chemical group 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
239000012153 distilled water Substances 0.000 claims 1
239000000839 emulsion Substances 0.000 claims 1
230000007515 enzymatic degradation Effects 0.000 claims 1
239000008103 glucose Substances 0.000 claims 1
229940047650 haemophilus influenzae Drugs 0.000 claims 1
208000006454 hepatitis Diseases 0.000 claims 1
231100000283 hepatitis Toxicity 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
239000002502 liposome Substances 0.000 claims 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
239000003921 oil Substances 0.000 claims 1
239000003960 organic solvent Substances 0.000 claims 1
230000003204 osmotic effect Effects 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
239000003755 preservative agent Substances 0.000 claims 1
239000003380 propellant Substances 0.000 claims 1
210000000664 rectum Anatomy 0.000 claims 1
201000004409 schistosomiasis Diseases 0.000 claims 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
230000009885 systemic effect Effects 0.000 claims 1
201000002311 trypanosomiasis Diseases 0.000 claims 1
201000008827 tuberculosis Diseases 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1
241000712461 unidentified influenza virus Species 0.000 claims 1
210000001215 vagina Anatomy 0.000 claims 1
238000009472 formulation Methods 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

OA60698A 1993-02-15 1995-08-11 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane OA10564A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK93170A DK17093D0 (da)	1993-02-15	1993-02-15	Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Publications (1)

Publication Number	Publication Date
OA10564A true OA10564A (en)	2002-06-20

Family

ID=8090567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60698A OA10564A (en)	1993-02-15	1995-08-11	A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane

Country Status (14)

Country	Link
US (1)	US5942237A (da)
EP (1)	EP0682528B1 (da)
JP (1)	JPH09508614A (da)
AT (1)	ATE195077T1 (da)
AU (1)	AU668290B2 (da)
CA (1)	CA2156084A1 (da)
DE (1)	DE69425427T2 (da)
DK (2)	DK17093D0 (da)
ES (1)	ES2150982T3 (da)
GR (1)	GR3034727T3 (da)
NO (1)	NO312057B1 (da)
OA (1)	OA10564A (da)
PT (1)	PT682528E (da)
WO (1)	WO1994017827A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9316745D0 (en)	1993-08-12	1993-09-29	Medeva Holdings Bv	Vaccine compositions
ATE226829T1 (de) *	1996-01-25	2002-11-15	Profylakse Aps	Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
IS4518A (is) *	1997-07-09	1999-01-10	Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group	Nýtt lyfjaform fyrir bóluefni
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
US7229621B2 (en) *	1998-10-20	2007-06-12	Torrey Pines Institute For Molecular Studies	Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) *	1999-02-12	1999-02-12	Pharmatrix Ab	Vaccine composition
EP1034792A1 (en) *	1999-03-11	2000-09-13	Pasteur Merieux Serums Et Vaccins	Intranasal delivery of pneumococcal polysaccharide vaccines
KR20020038771A (ko) *	1999-09-24	2002-05-23	장 스테판느	비내 인플루엔자 바이러스 백신
GB9924351D0 (en)	1999-10-14	1999-12-15	Brennan Frank	Immunomodulation methods and compositions
AU2002367976B2 (en) *	2001-06-05	2007-06-21	The Regents Of The University Of Michigan	Nanoemulsion vaccines
AU2002333194B2 (en) *	2001-08-16	2006-05-04	Lyfjathroun H.F., Biopharmaceuticals	A method of producing antibodies ex-vivo
KR100406503B1 (ko) *	2001-09-25	2003-11-19	한국과학기술연구원	폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
US20050063940A1 (en) *	2002-02-25	2005-03-24	Sveinbjorn Gizurarson	Bioadhesive agent
US6855332B2 (en) *	2002-07-03	2005-02-15	Lyfjathroun Hf.	Absorption promoting agent
BR0215954A (pt) *	2002-11-26	2005-09-13	Uc Tech	Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
US9717754B2 (en)	2003-02-27	2017-08-01	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
WO2005032462A2 (en)	2003-02-27	2005-04-14	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
US20070184058A1 (en) *	2003-02-27	2007-08-09	Yaron Ilan	Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US20050208083A1 (en)	2003-06-04	2005-09-22	Nanobio Corporation	Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2006097793A2 (en)	2004-04-15	2006-09-21	Chiasma, Ltd.	Compositions capable of facilitating penetration across a biological barrier
CA2596920C (en) *	2005-01-28	2015-05-05	North-West University	Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US20070054834A1 (en) *	2005-04-11	2007-03-08	Nanobio Corporation	Quaternary ammonium halides for treatment of infectious conditions
CA2618974C (en) *	2005-08-09	2014-01-28	Nanobio Corporation	Nanoemulsion compositions having anti-inflammatory activity
US9839685B2 (en) *	2006-04-13	2017-12-12	The Regents Of The University Of Michigan	Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en)	2006-04-13	2018-11-27	Regents Of The University Of Michigan	Compositions and methods for Bacillus anthracis vaccination
US20080038295A1 (en) *	2006-04-13	2008-02-14	Regents Of The University Of Michigan	Compositions and methods for orthopox virus vaccination
TW200824693A (en) *	2006-08-28	2008-06-16	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of clonazepam and methods of use thereof
EP2123296B1 (en) *	2007-01-31	2019-05-22	Hisamitsu Pharmaceutical Co., Inc.	Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
CA2685308A1 (en) *	2007-04-27	2009-01-29	Dow Global Technologies Inc.	Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2009143524A2 (en) *	2008-05-23	2009-11-26	The Regents Of The University Of Michigan	Nanoemulsion vaccines
ES3058497T3 (en)	2008-09-17	2026-03-11	Amryt Endo Inc	Pharmaceutical compositions comprising polypeptides and related methods of delivery
EP2442827B1 (en) *	2009-06-16	2016-01-06	The Regents of the University of Michigan	Nanoemulsion vaccines
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en)	2011-10-27	2013-05-01	Christopher L. Parks	Viral particles derived from an enveloped virus
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
WO2015064710A1 (ja)	2013-10-31	2015-05-07	久光製薬株式会社	アジュバント組成物、これを含むアジュバント製剤、及びキット
JP6652331B2 (ja) *	2014-05-30	2020-02-19	キリンホールディングス株式会社	乳酸菌免疫賦活作用増強組成物及び乳酸菌免疫賦活作用増強方法
PL3253401T3 (pl)	2015-02-03	2025-08-04	Amryt Endo, Inc.	Leczenie akromegalii oktreotydem doustnym
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
CN111721937B (zh) *	2019-03-29	2023-04-07	北京九强生物技术股份有限公司	人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1171125A (en) *	1966-06-08	1969-11-19	Glaxo Lab Ltd	Improvements in or relating to Injectable Preparations
US4315925A (en) *	1980-05-30	1982-02-16	University Of Kentucky Research Foundation	Method of administering natural female sex hormones
DE3446515A1 (de) *	1984-12-20	1986-06-26	Behringwerke Ag, 3550 Marburg	Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) *	1985-02-25	1986-08-28	Teijin Ltd	経鼻投与用粉末状組成物
JP2849632B2 (ja) *	1988-04-08	1999-01-20	社団法人北里研究所	ワクチン製剤
NL9000207A (da) *	1990-01-29	1991-08-16	Duphar Int Res
GB9018690D0 (en) *	1990-08-24	1990-10-10	Wellcome Found	Vaccines
WO1992018147A1 (en) *	1991-04-19	1992-10-29	Affinity Biotech, Inc.	Convertible microemulsion formulations
NZ244102A (en) *	1991-08-26	1996-12-20	Scripps Research Inst	Peptides inducing cytotoxic t lymphocyte responses against hbv antigen and their use
CA2083553A1 (en) *	1991-11-25	1993-05-26	Kuniharu Seki	Immunogen composition

1993
- 1993-02-15 DK DK93170A patent/DK17093D0/da not_active Application Discontinuation
1994
- 1994-02-14 ES ES94907503T patent/ES2150982T3/es not_active Expired - Lifetime
- 1994-02-14 AT AT94907503T patent/ATE195077T1/de not_active IP Right Cessation
- 1994-02-14 EP EP94907503A patent/EP0682528B1/en not_active Expired - Lifetime
- 1994-02-14 WO PCT/DK1994/000062 patent/WO1994017827A1/en not_active Ceased
- 1994-02-14 AU AU61065/94A patent/AU668290B2/en not_active Ceased
- 1994-02-14 US US08/501,112 patent/US5942237A/en not_active Expired - Fee Related
- 1994-02-14 PT PT94907503T patent/PT682528E/pt unknown
- 1994-02-14 DK DK94907503T patent/DK0682528T3/da active
- 1994-02-14 JP JP6517549A patent/JPH09508614A/ja not_active Ceased
- 1994-02-14 CA CA002156084A patent/CA2156084A1/en not_active Abandoned
- 1994-02-14 DE DE69425427T patent/DE69425427T2/de not_active Expired - Fee Related
1995
- 1995-08-11 OA OA60698A patent/OA10564A/en unknown
- 1995-08-14 NO NO19953182A patent/NO312057B1/no unknown
2000
- 2000-10-30 GR GR20000402416T patent/GR3034727T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU668290B2 (en)	1996-04-26
NO312057B1 (no)	2002-03-11
EP0682528A1 (en)	1995-11-22
ATE195077T1 (de)	2000-08-15
DK17093D0 (da)	1993-02-15
DE69425427D1 (de)	2000-09-07
ES2150982T3 (es)	2000-12-16
NO953182D0 (no)	1995-08-14
US5942237A (en)	1999-08-24
PT682528E (pt)	2001-01-31
DE69425427T2 (de)	2001-02-08
EP0682528B1 (en)	2000-08-02
AU6106594A (en)	1994-08-29
CA2156084A1 (en)	1994-08-18
GR3034727T3 (en)	2001-01-31
NO953182L (no)	1995-10-12
WO1994017827A1 (en)	1994-08-18
JPH09508614A (ja)	1997-09-02
DK0682528T3 (da)	2000-12-27

Publication	Publication Date	Title
EP0682528B1 (en)	2000-08-02	A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
US6391318B1 (en)	2002-05-21	Vaccine compositions including chitosan for intranasal administration and use thereof
US5961970A (en)	1999-10-05	Submicron emulsions as vaccine adjuvants
US6514503B1 (en)	2003-02-04	Antigen delivery system
RU2347586C2 (ru)	2009-02-27	Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
US4455142A (en)	1984-06-19	Method of coadministering an antigen and an immunopotentiator
Newman et al.	1998	Use of nonionic block copolymers in vaccines and therapeutics
US20120014991A1 (en)	2012-01-19	Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
Glück	1992	Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens
CN101917985B (zh)	2014-07-02	糖基神经酰胺增强对抗原的免疫反应的用途
CA2258017A1 (en)	1997-12-18	Immunstimulating lipid formulation
Smith et al.	1998	Immune stimulating complexes as mucosal vaccines
KR20030015288A (ko)	2003-02-20	보조제 배합물로서의 큐에스-21 및 아이엘-12
EP1150713B1 (en)	2005-04-27	Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
RU2311926C2 (ru)	2007-12-10	Носитель и адъювант для антигенов
McGhee et al.	1989	Oral immunization: a summary
AU705452C (en)	2000-02-24	Vaccine compositions for intranasal administration comprising chitosan and use thereof